Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Mar 18;86(6):1017-8.
doi: 10.1038/sj.bjc.6600164.

Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy

Free PMC article

Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy

R Andres et al. Br J Cancer. .
Free PMC article

Abstract

British Journal of Cancer (2002) 86, 1017–1018. DOI: 10.1038/sj/bjc/6600164 www.bjcancer.com

© 2002 Cancer Research UK

PubMed Disclaimer

References

    1. AntmanKAyashLEliasAet al1992A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy J Clin Oncol 10102110 - PubMed
    1. IñiguezCLarrodePMayordomoJIet al1998Reversible peripheral neuropathy induced by a single administration of high-dose paclitaxel Neurology 51868870 - PubMed
    1. IslaDMayordomoJIYuberoAet al1998Durable response in metastatic breast cancer with high-dose paclitaxel in combination with cyclophosphamide, carboplatin, thiotepa and stem cell rescue Proc Am Soc Clin Oncol 17148a
    1. LotzJPCureHJanvierMet al1999High-dose chemotherapy with hematopoietic stem cell transplantation for metastatic breast cancer: results of the French Protocol PEGASE 04 Proc Am Soc Clin Oncol 1843a
    1. MayordomoJIYuberoACajalRet al1997Phase I trial of high-dose paclitaxel in combination with cyclophosphamide, thiotepa and carboplatin with autologous peripheral blood stem cell rescue Proc Am Soc Clin Oncol 16102

MeSH terms